

Publ 26
Sub 26
Please add the following claims 36-40:

26
36. A pharmaceutical formulation for bone and/or cartilage formation comprising an effective amount of a BMP-8 protein in a pharmaceutically acceptable vehicle.

27
37. A composition of claim *26* further comprising a matrix for supporting said composition and providing a surface for bone and/or cartilage formation.

28
38. The composition of claim *27* wherein said matrix comprises a material selected from the group consisting of hydroxyapatite, collagen, polylactic acid and tricalcium phosphate.

29
39. A pharmaceutical composition for wound healing and tissue repair said composition comprising an effective amount of a BMP-8 protein in a pharmaceutically acceptable vehicle.

30
40. A BMP-8 protein comprising a disulfide-linked dimer wherein at least one subunit comprises amino acid #4 (Ala) through #142 (His) of SEQ ID NO:14.

REMARKS

An amended Sequence Listing, computer readable form and Statement Pursuant to §1.825(a) and (b) are submitted herewith. The specification and claims have been amended to specifically reference the SEQ ID and position numbers for the SEQ ID. Reference to Figure 2 has been deleted. Claims 1, 4, 5, and 10-12 have been amended and claims 36-40 added.

USSN 08/319,831

April 21, 1995

Page 8

New claims 36-40 correspond with claims 21-25 of the originally filed claims. Basis for these claims appears in the specification, for example on page 2, lines 1-7; page 4, line 35 - page 5, line 6; page 8, lines 3-13; page 11, lines 21-32; and page 16, lines 10-28.

Respectfully submitted,



Ellen J. Kapinos

Reg. No. 32,245

Attorney for Applicants

LEGAL AFFAIRS

Genetics Institute, Inc.

87 CambridgePark Drive

Cambridge, MA 02140

(617) 498-8622 Ext. 8622